
Diagnosis and Management of Testicular Cancer

Susanne Krege
Editor

Diagnosis and Management of Testicular Cancer

The European Point of View

 Springer

Editor
Susanne Krege
Kliniken Essen-Mitte
Klinik für Urologie
Essen
Germany

ISBN 978-3-319-17466-2 ISBN 978-3-319-17467-9 (eBook)
DOI 10.1007/978-3-319-17467-9

Library of Congress Control Number: 2015941277

Springer Cham Heidelberg New York Dordrecht London
© Springer International Publishing Switzerland 2015

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

Springer International Publishing AG Switzerland is part of Springer Science+Business Media (www.springer.com)

Contents

Part I Overview of the Latest Recommendations of the European Germ Cell Cancer Group

- 1 Latest Recommendations of the European
Germ Cell Cancer Group on Diagnosis and
Treatment of Germ Cell Cancer 3**
Susanne Krege

Part II Special Topics About Controversial Aspects, New Results from Studies, Which Might Change Treatment Recommendations and Long-Term-Survivorship

- 2 Is There Still an Indication for Radiotherapy
in Seminoma Clinical Stages I–IIA/B? 19**
Sophie Dorothea Fosså and Klaus-Peter Dieckmann
- 3 How Should We Treat Clinical Stage I (CSI) Nonseminoma 25**
Torgrim Tandstad
- 4 Is There Still an Indication for Primary RPLND
in Clinical Stage I Non-seminoma? 29**
Nicola Nicolai and Alessandro Crestani
- 5 Metastatic Germ Cell Cancer:
The Intermediate-Prognosis Risk Category 55**
Carsten Bokemeyer and Christoph Seidel
- 6 Poor-Prognosis Germ Cell Tumours 65**
Karim Fizazi and Stephane Culine
- 7 How Should Patients with Recurrent Disease
Be Treated Actually? 73**
Anja Lorch

8	Prognostic Factors at Initial Presentation and in Recurrent Disease	81
	Jörg Beyer	
9	Postchemotherapy Retroperitoneal Lymph Node Dissection	91
	Axel Heidenreich	
10	What Are the Recent Recommendations for Follow-Up in Testicular Cancer?	99
	Richard Cathomas and Michael Hartmann	
11	What Are the Long-Term Toxicities to Be Controlled and Treated?	115
	J. Oldenburg, H.S. Haugnes, and S.D. Fosså	
12	Consequences of the Disease and Its Treatment Concerning Sexuality and Fertility.	127
	Sabine Kliesch	

Contributors

Jörg Beyer Department of Oncology, University Hospital Zürich, Zürich, Switzerland

Carsten Bokemeyer Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Hospital Hamburg-Eppendorf, Hamburg, Germany

Richard Cathomas Department of Internal Medicine/ Section Oncology, Kantonsspital Graubünden, Chur, Switzerland

Alessandro Crestani Department of Urology/ Testis Surgery Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy

Stephane Culine Department of Medical Oncology, Hospital Saint Louis, University of Paris VII, Paris, France

R. de Wit Erasmus University Medical Center/ Cancer Institute, Rotterdam, The Netherlands

Klaus-Peter Dieckmann Department of Urology, Albertinen-Krankenhaus, Hamburg, Germany

Karim Fizazi, MD, PhD Department of Cancer Medicine, University of Paris Sud, Institut Gustave Roussy, Villejuif, France

Sophie Dorothea Fosså Oslo University Hospital, The Norwegian Radium Hospital, National Advisory Unit for Late Effects after Cancer Therapy, Oslo, Norway

Michael Hartmann Department of Oncology/ Interdisciplinary Testis Cancer Unit, University Hospital Hamburg-Eppendorf, Hamburg, Germany

H.S. Haugnes Department of Oncology, University Hospital of North Norway, Tromsø, Norway

Axel Heidenreich Department of Urology, University Hospital Aachen, Aachen, Germany

Sabine Kliesch Department of Clinical Andrology, Center of Reproductive Medicine and Andrology WHO Collaboration Center, EAA Training Center, University Hospital Münster, Münster, Germany

Susanne Krege Klinik für Urologie, Kliniken Essen-Mitte, Essen, Germany

Anja Lorch Genitourinary Medical Oncology/ Department of Urology, University Hospital Düsseldorf, Düsseldorf, Germany

Nicola Nicolai Department of Urology/ Testis Surgery Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy

Jan Oldenburg Department of Oncology, Akershus University Hospital, Lorenskog and Oslo University Hospital, Lorenskog, Norway

Christoph Seidel Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Hospital Hamburg-Eppendorf, Hamburg, Germany

Torggrim Tandstad, MD, PhD Department of Oncology, St. Olavs University Hospital, Trondheim, Norway